If you have been reading about GLP-1 receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-16. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
=== Engine coolant standards === The Volkswagen Group has been particularly committed to the development of coolants and their standards (VW TL 774) in collaboration with Haertol Chemie from Magdeburg. VW standards include: G11, G12, G12+, G12++, G13 and G12evo. Another company involved in the development is BASF (Glysantin), whose standards are: G30, G40, G48, G05, G33, and G34. Volkswagen Group:
ambassador to Israel Matt Gonzalez (1987), Green Party San Francisco mayoral candidate and independent 2008 candidate for vice president running with Ralph Nader Tim Kelly (1989), 74th mayor of Chattanooga, Tennessee Julie Menin (1989), former chairperson of Manhattan Community Board 1 and former commissioner of the New York City Department of Consumer Affairs Dave Hunt (1990), 65th speaker of the Oregon House of Representatives and majority leader 2007–2009 Michael Leiter (1991), principal deputy director of the National Counterterrorism Center; former deputy chief of staff for the Office of the Director of National Intelligence Melissa Mark-Viverito (1991), speaker of the New York City Council Benjamin Lawsky (1992), attorney and New York City's first superintendent of financial services Peter Hatch (1992), commissioner of the New York City Department of Consumer and Worker Protection Eric Garcetti (1992), member of the Los Angeles City Council and current mayor of Los Angeles, nominee to be U.S. ambassador to India Rohit Aggarwala (1993), commissioner of the New York City Department of Environmental Protection Matt Brown (1993), secretary of state of Rhode Island 2003–2007; co-founder of non-partisan group Global Zero Alan D.
Public health laboratories (PHLs) or National Public Health Laboratories (NPHL) are governmental reference laboratories that protect the public against diseases and other health hazards. The 2005 International Health Regulations came into force in June 2007, with 196 binding countries that recognised that certain public health incidents, extending beyond disease, ought to be designated as a Public Health Emergency of International Concern (PHEIC), as they pose a significant global threat. The PHLs serve as national hazard detection centres, and forward these concerns to the World Health Organization.
has stated that these are the only actions known at present which could explain or at least contribute to the antidepressant effects of trimipramine. That said, blockade of the 5-HT2A, 5-HT2C, and α2-adrenergic receptors, as with mirtazapine, has also been implicated in antidepressant effects. In any case, there is also clinical and animal evidence that trimipramine does not inhibit the reuptake of monoamines. Unlike other TCAs, it does not downregulate β3-adrenergic receptors, which is likely the reason that it does not cause orthostatic hypotension. It can be safely combined with MAOIs apparently without risk of serotonin syndrome or hypertensive crisis. Indeed, in rabbits, whereas hyperpyrexia (a symptom of serotonin syndrome) occurs with imipramine and an MAOI and to a lesser extent with amitriptyline and an MAOI, it does not occur at all with trimipramine and an MAOI, likely due to trimipramine's lack of serotonin reuptake inhibition.
Sources: en.wikipedia.org
==== Phenotypes ==== For all their genetic improvements, the Culture is by no means eugenically uniform. Human members in the Culture setting vary in size, colour and shape as in reality, and with possibly even further natural differences: in the novella The State of the Art, it is mentioned that a character "looks like a Yeti", and that there is variance among the Culture in minor details such as the number of toes or of joints on each finger. It is mentioned in Excession that:
=== Blood-feeding insects === Many blood-feeding insects like horseflies or mosquitoes inject multiple bioactive compounds into their prey. These insects have been used by practitioners of Eastern Medicine for hundreds of years to prevent blood clot formation or thrombosis. However, modern medical research has only recently begun to investigate the drug development potential of blood-feeding insect saliva. These compounds in the saliva of blood feeding insects are capable of increasing the ease of blood feeding by preventing coagulation of platelets around the wound and provide protection against the host's immune response. Currently, over 1280 different protein families have been associated with the saliva of blood feeding organisms.
=== Methionine synthase reductase activity === Involved in the reductive remethylation of cob(II)alamin using S-adenosylmethionine as a methyl donor. Catalyses the reaction: [methionine synthase]- cob(II)alamin + NADPH + H+ + S-adenosylmethionine → [methionine synthase]-methylcob(I)alamin + S-adenosylhomocysteine + NADP+.
Nuclear export of SENP2 additionally downregulates endothelial nitric oxide synthase, eNOS while it upregulates inflammatory adhesion molecules. As eNOS is required for healthy vascular physiology, pathological oxidative stress ensues in vascular endothelial cells. With the oxidative stress comes subsequent accumulation of cellular lipids; this results in the inflammatory foamy cell state that is typified by atherosclerosis as well as the similarly inflammatory myelin-laden macrophages known to produce chronic inflammation in SCI. In cardiovascular disease, many proteins are subject to SUMOylation. To say SUMOylation itself is bad or good regarding this or any other class of disease is to overlook the role of the multiple proteins in question. One common denominator among many conditions is fibrosis; in myocardial fibrosis, PPARγ1 is understood to have a role in regulating expression of some key genes, and its transcriptional activity is generally inhibited by SUMOylation. Therefore, one possible therapeutic intervention in the case of cardiac hypertrophy may be countering the SUMOylation of PPARγ1. In neurodegenerative disease, we often observe pathological accumulation of proteins. Inclusion bodies form when for example, the Huntington's disease protein, aptly named Huntingtin, accumulates and folds into a form which is impervious to the proteasome.
Chamaecostus cuspidatus, common name fiery costus or spiral flag, is a species of herbaceous plant in the family Costaceae native to eastern Brazil (States of Bahia and Espírito Santo). In India, it is known as insulin plant for its purported anti-diabetic properties. Chamaecostus cuspidatus has large fleshy-looking leaves. The undersides of these large, smooth, dark green leaves have light purple shade. The leaves are spirally arranged around the stem, forming attractive, arching clumps arising from underground rootstocks. The maximum height of these plants is about two feet. The flowers are orange in color and are 1.5 in (3.8 cm) in diameter. Flowering occurs during the warm months and they appear to be cone-like heads at the tips of branches.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.